The report surveyed payers around the world to better understand their perspective on the COVID-19 pandemic and what it could mean for the industry. ZS conducted 45-minute surveys with 25 global health plans from March 30 to April 7.
Here are the 10 therapy areas U.S. payers said they are prioritizing right now, ranked from highest to lowest:
1. Vaccines
2. Anti-infectives
3. Oncology
4. Cell and gene therapy
5. Biosimilars
6. Acute care medicines
7. Autoimmune diseases
8. Orphan diseases
9. Generics
10. Medical devices
Access the full report here.
More articles on payers:
UnitedHealth to give members $1.5B in discounts
Humana waives costs for primary care, behavioral health visits for 4.5 million members
Health Care Service Corp. taps new CEO
Leave a Reply